Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors.

abstract：:Suicide gene therapy using herpes simplex virus type-1 (HSV-1) thymidine kinase (TK) is a widely exploited approach for gene therapy of cancer and other hyperproliferative disorders. Despite its popularity, clinical success has been so far hampered mostly by the relative inefficiency of TK gene transfer and its limite...

journal_title：Cancer gene therapy

authors： Tasciotti E,Zoppè M,Giacca M

更新日期：2003-01-01 00:00:00

abstract：:We have used the tetracycline (tet)-regulated system as described previously to evaluate the applicability of controlled gene expression in cancer gene therapy. As a model gene, we used the human interleukin-2 (IL-2) gene, which has been placed under the transcriptional control of the tetO/promoter. Human melanoma cel...

journal_title：Cancer gene therapy

authors： Pitzer C,Schindowski K,Pomer S,Wirth T,Zöller M

更新日期：1999-03-01 00:00:00

abstract：:Recurrent fusion genes (FGs) with clinical significances in leukemias are mainly mutually exclusive, and the coexistence of different FGs has been rarely reported. In this study, we retrospectively analyzed the incidence, genetic characteristics, and prognosis of leukemias with concurrent pathogenic FGs, which commonl...

journal_title：Cancer gene therapy

authors： Chen X,Wang F,Wang T,Zhang Y,Ma X,Yuan L,Teng W,Guo L,Liu M,Liu M,Chen J,Nie D,Zhang Y,Zhou X,Wang M,Chen KN,Zhu P,Liu H

更新日期：2020-02-01 00:00:00

abstract：:Engineered retroviruses are widely used vectors for cancer gene therapy approaches. However, the ability to target cells of therapeutic interest while controlling the expression of the transferred genes would improve both the efficiency and the safety of viral vectors. In this study, we investigated the ability of a r...

journal_title：Cancer gene therapy

authors： Nguyen TH,Loux N,Dagher I,Vons C,Carey K,Briand P,Hadchouel M,Franco D,Jouanneau J,Schwall R,Weber A

更新日期：2003-11-01 00:00:00

abstract：:The original version of this Article contained an error in the spelling of the author Ahmed Abdelanabi, which was incorrectly given as Abdelanabi Ahmed. This has now been corrected in both the PDF and HTML versions of the Article. ...

journal_title：Cancer gene therapy

authors： Ahmed SG,Abdelanabi A,Doha M,Brenner GJ

更新日期：2020-04-01 00:00:00

abstract：:The herpes simplex virus thymidine kinase gene (HSV-TK) in combination with ganciclovir (GCV), is currently being used in gene therapy-based clinical trials for cancer treatment. Its therapeutic effect is based on a "bystander effect" whereby HSV-TK gene-modified tumor cells are toxic to nearby unmodified tumor cells ...

journal_title：Cancer gene therapy

authors： Ramesh R,Munshi A,Abboud CN,Marrogi AJ,Freeman SM

更新日期：1996-11-01 00:00:00

abstract：:The immune responses of 10 patients with advanced non-small cell lung cancer receiving monthly intratumoral injections of a recombinant adenovirus containing human wild-type p53 (Ad-p53) to adenovirus and transgene antigens were studied. The predominate cellular and humoral immune responses as measured by lymphocyte p...

journal_title：Cancer gene therapy

authors： Yen N,Ioannides CG,Xu K,Swisher SG,Lawrence DD,Kemp BL,El-Naggar AK,Cristiano RJ,Fang B,Glisson BS,Hong WK,Khuri FR,Kurie JM,Lee JJ,Lee JS,Merritt JA,Mukhopadhyay T,Nesbitt JC,Nguyen D,Perez-Soler R,Pisters KM,P

更新日期：2000-04-01 00:00:00

abstract：:The aim of the present study is to identify the optimal anticancer agents for use in combination with gene therapy using wild-type (wt) p53 gene transfer. We used adenoviral vectors expressing human wt p53 (AdCAp53) and investigated the effects of wt p53 gene transfer in combination with 12 anticancer agents on a huma...

journal_title：Cancer gene therapy

authors： Osaki S,Nakanishi Y,Takayama K,Pei XH,Ueno H,Hara N

更新日期：2000-02-01 00:00:00

abstract：:Newcastle disease virus (NDV), an avian paramyxovirus, has a potential oncolytic effect that may be of significance in the treatment of a variety of cancer diseases. An attenuated lentogenic isolate of NDV (HUJ) demonstrated a selective cytopathic effect upon a panel of human and mouse lung tumor cells, as compared to...

journal_title：Cancer gene therapy

authors： Yaacov B,Eliahoo E,Lazar I,Ben-Shlomo M,Greenbaum I,Panet A,Zakay-Rones Z

更新日期：2008-12-01 00:00:00

abstract：:p53 mutations are common genetic alterations in human cancer. Gene transfer of a wild-type (wt) p53 gene reverses the loss of normal p53 function in vitro and in vivo. A phase I dose escalation study of single intratumoral (i.t.) injection of a replication-defective adenoviral expression vector containing wt p53 was c...

journal_title：Cancer gene therapy

authors： Dummer R,Bergh J,Karlsson Y,Horowitz JA,Mulder NH,Huinink DTB,Burg G,Hofbauer G,Osanto S

更新日期：2000-07-01 00:00:00

abstract：:Herpes simplex virus type 1 (HSV-1) is one of the most widely studied viruses for oncolytic virotherapy. In squamous cell carcinoma (SCC) cells, the role of autophagy induced by neurovirulence gene-deficient HSV-1s in programmed cell death has not yet been elucidated. The oncolytic HSV-1 strain RH2, which lacks the γ3...

journal_title：Cancer gene therapy

authors： Furukawa Y,Takasu A,Yura Y

更新日期：2017-09-01 00:00:00

abstract：:Gliomas express a higher amount of Fas than normal brain tissue. It is of interest to know whether expression of the Fas receptor is unfavorable to the antiapoptotic pathways in gliomas. In this study, we introduced the Fas gene via an adenovirus vector (Adeno-Fas) into the A-172, U251, and U-373 MG glioma cell lines,...

journal_title：Cancer gene therapy

authors： Shinoura N,Ohashi M,Yoshida Y,Kirino T,Asai A,Hashimoto M,Hamada H

更新日期：2000-02-01 00:00:00

abstract：:Specificity is a prerequisite for systemic gene therapy of hepatocarcinoma. In vitro, the tumor-specific viral death effector Apoptin selectively induces apoptosis in malignant hepatic cells. Intratumoral treatment of xenografted subcutaneous hepatomas with Apoptin results in tumor regression. Here, we report a system...

journal_title：Cancer gene therapy

authors： Peng DJ,Sun J,Wang YZ,Tian J,Zhang YH,Noteborn MH,Qu S

更新日期：2007-01-01 00:00:00

abstract：:MicroRNAs (miRNAs) are a type of small noncoding RNAs that have a vital role in basic biological processes such as cellular growth, division and apoptosis. A change in the expression of miRNAs can induce many diseases. Recently, the role of miRNA in some of the cancers as a tumor suppressor and oncogene has been recog...

journal_title：Cancer gene therapy

authors： Ahmadi S,Sharifi M,Salehi R

更新日期：2016-07-01 00:00:00

abstract：:Cytotoxicity is an important function of the immune system that results in the destruction of cellular targets by humoral and/or cellular mechanisms. We wanted to assess the possibility of targeting the lytic function of immune cells toward cancer cells, which express the gene coding for a known tumor antigen (Ag) (GA...

journal_title：Cancer gene therapy

authors： Paul S,Bizouarne N,Dott K,Ruet L,Dufour P,Acres RB,Kieny MP

更新日期：2000-04-01 00:00:00

abstract：:Circular RNAs (circRNAs) are involved in the regulation of many pathophysiological processes as non-coding RNAs. This study focuses on the role of circRACGAP1 in the development of non-small cell lung cancer (NSCLC). Expression patterns of circRACGAP1 and miR-144-5p in NSCLC tissues and cell lines were quantified by q...

journal_title：Cancer gene therapy

authors： Lu M,Xiong H,Xia ZK,Liu B,Wu F,Zhang HX,Hu CH,Liu P

更新日期：2020-08-11 00:00:00

abstract：:We have previously described oncolytic adenovirus (Ad) vectors KD3 and KD3-interferon (IFN) that were rendered cancer-specific by mutations in the E1A region of Ad; these mutations abolish binding of E1A proteins to p300/CBP and pRB. The antitumor activity of the vectors was enhanced by overexpression of the Adenoviru...

journal_title：Cancer gene therapy

authors： Shashkova EV,Kuppuswamy MN,Wold WS,Doronin K

更新日期：2008-02-01 00:00:00

abstract：:Lung cancer is one of the leading causes of death in the world. The underlying cause for lung cancer has been attributed to various factors that include alteration and mutation in the tumor suppressor genes. Restoration of normal function of the tumor suppressor gene is a potential therapeutic strategy. Recent studies...

journal_title：Cancer gene therapy

authors： Ito I,Ji L,Tanaka F,Saito Y,Gopalan B,Branch CD,Xu K,Atkinson EN,Bekele BN,Stephens LC,Minna JD,Roth JA,Ramesh R

更新日期：2004-11-01 00:00:00

abstract：:Myeloid leukemia (ML) is heterogeneous cancer classified by abnormal growth of myeloid cells due to genetic aberrations and mutations. It is generally categorized by clonal disorders of hematopoietic stem cells and differentiation. The molecular mechanism behind the myeloid malignancies is not yet known, but recent se...

journal_title：Cancer gene therapy

authors： Panagal M,S R SK,P S,M B,M K,Gopinathe V,Sivakumare P,Sekar D

更新日期：2018-08-01 00:00:00

abstract：:Although early stage cholangiocarcinoma (CC) can be cured by surgical extirpation, the options for treatment of advanced stage CC are very few and suboptimal. Oncolytic virotherapy using replication-competent vaccinia virus (VACV) is a promising new strategy to treat human cancers. The ability of oncolytic VACV GLV-1h...

journal_title：Cancer gene therapy

authors： Pugalenthi A,Mojica K,Ady JW,Johnsen C,Love D,Chen NG,Aguilar RJ,Szalay AA,Fong Y

更新日期：2015-12-01 00:00:00

abstract：:Current oncolytic viruses exert only limited antitumor activity on their own. There is a need to increase their oncolytic capability. We evaluated the effect of a differentiating reagent, hexamethylene bisacetamide (HMBA), on the antitumor activity of a gamma(1)34.5-deficient herpes simplex virus type 1 (HSV-1) R849 f...

journal_title：Cancer gene therapy

authors： Naito S,Obayashi S,Sumi T,Iwai S,Nakazawa M,Ikuta K,Yura Y

更新日期：2006-08-01 00:00:00

abstract：:We examined the host immune response to the poorly immunogenic B16-BL6 melanoma, which was transduced to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) (450 ng/10(6)/24 h). Tumor growth after subcutaneous inoculation was not significantly altered, although an influx of neutrophils and monocytes/macr...

journal_title：Cancer gene therapy

authors： Arca MJ,Krauss JC,Aruga A,Cameron MJ,Shu S,Chang AE

更新日期：1996-01-01 00:00:00

abstract：:Cancer is one of the main problems in public health worldwide. Despite rapid advances in the diagnosis and treatment of cancer, the efficacy of current treatment strategies is still limited. There are promising new results in animal models whereby mesenchymal stem cells (MSCs) can be used as vehicles for targeted ther...

journal_title：Cancer gene therapy

authors： Mohammadi M,Jaafari MR,Mirzaei HR,Mirzaei H

更新日期：2016-09-01 00:00:00

abstract：:Vesicular stomatitis virus (VSV) is being developed for cancer therapy. We created a recombinant replicating VSV (rrVSV) that preferentially infected Her2/neu expressing breast cancer cells. We now used this rrVSV to treat macroscopic peritoneal tumor implants of a mouse mammary tumor cell line stably transfected to e...

journal_title：Cancer gene therapy

authors： Gao Y,Whitaker-Dowling P,Griffin JA,Barmada MA,Bergman I

更新日期：2009-01-01 00:00:00

abstract：:Poor tumor targeting of oncolytic adenoviruses (OAdv) after systemic administration is considered a major limitation for virotherapy of disseminated cancers. The benefit of using mesenchymal stem cells as cell carriers for OAdv tumor targeting is currently evaluated not only in preclinical models but also in clinical ...

journal_title：Cancer gene therapy

authors： Barlabé P,Sostoa J,Fajardo CA,Alemany R,Moreno R

更新日期：2020-05-01 00:00:00

abstract：:Mammary carcinomas that develop in C3 (1)/SV40 T- antigen (TAg) transgenic mice have lost the p53-mediated induction of p21, leading to increased cellular proliferation and significant elevations of cyclins and Cdks. To test whether p21 could serve as a target for anticancer therapy for this mammary cancer model, a re...

journal_title：Cancer gene therapy

authors： Shibata MA,Yoshidome K,Shibata E,Jorcyk CL,Green JE

更新日期：2001-01-01 00:00:00

abstract：:As of January 2005, there were 1020 gene therapy clinical trials ongoing worldwide with 675 or 66.2% devoted to cancer gene therapy. The majority are occurring in the US and Europe (http://www.wiley.co.uk/genetherapy/clinical/). At the present time, to our knowledge there are no trials that employ gene delivery of Fas...

journal_title：Cancer gene therapy

authors： Norris JS,Bielawska A,Day T,El-Zawahri A,ElOjeimy S,Hannun Y,Holman D,Hyer M,Landon C,Lowe S,Dong JY,McKillop J,Norris K,Obeid L,Rubinchik S,Tavassoli M,Tomlinson S,Voelkel-Johnson C,Liu X

更新日期：2006-12-01 00:00:00

abstract：:Multiple myeloma (MM) is one of hematological malignancies, characterized by malignant proliferation of plasma cells. Biomarkers play an important role in evaluating the development and prognosis of MM. Ubiquitin-conjugating enzyme E2T (UBE2T) is served to connect with particular E3 ubiquitin ligase to degraded-relate...

journal_title：Cancer gene therapy

authors： Zhang W,Zhang Y,Yang Z,Liu X,Yang P,Wang J,Hu K,He X,Zhang X,Jing H

更新日期：2019-11-01 00:00:00

abstract：:Oncolytic viruses (OVs) have shown great anti-cancer potential in animal models, but only modest success in early clinical trials. A better understanding of the mechanisms underlining OV efficacy is needed to resolve this discrepancy. In the clinic, OV therapy will likely be combined with traditional chemotherapy, und...

journal_title：Cancer gene therapy

authors： Granot T,Meruelo D

更新日期：2012-08-01 00:00:00

abstract：:Targeting tumor vasculature represents an interesting approach for the treatment of solid tumors. The alpha v beta 3 integrins have been found to be specifically associated with angiogenesis in tumors. By using bacteriophage display technology, Ruoslahti et al found that a group of peptides containing the RGD (Arg-Gly...

journal_title：Cancer gene therapy

authors： Li J,Ji J,Holmes LM,Burgin KE,Barton LB,Yu X,Wagner TE,Wei Y

更新日期：2004-05-01 00:00:00